Products for Research Use Only

Ticagrelor (Standard)

CAT: 0804-HY-10064R-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-10064R-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Ticagrelor (Standard) is the analytical standard of Ticagrelor. This product is intended for research and analytical applications. Ticagrelor (AZD6140) is a reversible oral P2Y12 receptor antagonist for the treatment of platelet aggregation.
CAS Number
274693-27-5
Product Name Alternative
AZD6140 (Standard) ; AR-C 126532XX (Standard)
UNSPSC
12352005
Hazard Statement
H315-H319-H335
Target
P2Y Receptor; Reference Standards
Type
Reference Standards
Related Pathways
GPCR/G Protein; Others
Field of Research
Cardiovascular Disease; Cancer
Assay Protocol
https://www.medchemexpress.com/ticagrelor-standard.html
Smiles
O[C@H]1[C@@H](O)[C@H](N2N=NC3=C(N[C@H]4[C@H](C5=CC=C(F)C(F)=C5)C4)N=C(SCCC)N=C32)C[C@@H]1OCCO
Molecular Formula
C23H28F2N6O4S
Molecular Weight
522.57
Precautions
P261-P264-P271-P280-P302+P352-P304+P340-P305+P351+P338-P362+P364-P403+P233-P405-P501
References & Citations
[1]Aungraheeta R, et al. Inverse agonism at the P2Y12 receptor and ENT1 transporter blockade contribute to platelet inhibition by ticagrelor. Blood. 2016 Dec 8;128 (23) :2717-2728.|[2]Gebremeskel S, et al. The reversible P2Y12 inhibitor ticagrelor inhibits metastasis and improves survival in mouse models of cancer. Int J Cancer. 2015 Jan 1;136 (1) :234-40.|[3]Sugidachi A, et al. A comparison of the pharmacological profiles of prasugrel and ticagrelor assessed by platelet aggregation, thrombus formation and haemostasis in rats. Br J Pharmacol. 2013 May;169 (1) :82-9.
Shipping Conditions
Room temperature
Scientific Category
Reference Standards